Therapeutics: Blocking RAS effects

摘要

Owing to their driver status in many cancers, members of the RAS family of oncoproteins have been strongly pursued as drug targets. However, inhibitors of proteins that farnesylate RAS proteins have shown limited clinical efficacy, hence alternative routes to RAS inhibition are required. A recent study has identified new RAS-binding inhibitors that can block RAS effector functions and that show antitumour effects in RAS-mutant tumours.